Menu Philippe 4/A

4/A · SOPHiA GENETICS SA · Filed Apr 8, 2026

AI-generated summary of this filing

Updated Apr 8, 2026

SOPH CMO Philippe Menu Receives RSU Award

What Happened

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA (SOPH), received equity awards on April 2, 2026: 112,936 RSUs and 164,671 RSUs reported as derivative/contingent rights (total 277,607 RSUs). The awards were granted at $0.00 (no cash paid).
The Form 4/A amends the April 3, 2026 filing to correct the amount of securities beneficially owned following the transaction; the corrected total ownership is 286,552 ordinary shares (see footnote F2).

Key Details

Transaction date: April 2, 2026; Grant/award code: A; price reported: $0.00.
Shares reported acquired: 112,936 (direct RSUs) + 164,671 (derivative RSUs) = 277,607 RSUs.
Shares beneficially owned following transaction (corrected): 286,552 ordinary shares (per F2).
Vesting (per footnotes): F1 — each RSU converts to one share, 25% vests April 2, 2027, remaining 75% vest in equal quarterly installments through April 2, 2030. F3 references a related option vesting schedule (25% Apr 2, 2027, then equal monthly installments through Apr 2, 2030).
Filing status: Amended Form 4/A filed April 8, 2026 to correct the previously reported ownership figure; original Form 4 was filed April 3, 2026.

Context

These are time-vested RSU awards (contingent on continued service), not open-market purchases or sales — they do not represent an immediate market purchase or sale.
No cash changed hands for the grant; RSUs typically convert to shares as they vest. This award should be viewed as compensation/retention rather than a direct insider bullish/sell signal.
The amendment corrects reporting but does not change the nature of the award.

Form 4/AAmended

Period: 2026-04-02

Chief Medical Officer

Transactions

Award
Ordinary Shares
[F1][F2]
2026-04-02+112,936→ 286,552 total
Award
Share Option (Right to Buy)
[F3]
2026-04-02+164,671→ 164,671 total
Exercise: $5.04Exp: 2036-04-02→ Ordinary Shares (164,671 underlying)

Footnotes (3)

[F1]Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
[F2]This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 286,552 ordinary shares.
[F3]The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Signature

/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu|2026-04-08

1 file